Former Merck & Co., Inc.
Susan Rohrer has over 23 years of experience in the pharmaceutical industry and served in a variety of roles during her tenure at Merck & Co. Prior to joining Merck’s Licensing organization in 2004, she was a Senior Director of Biology & Drug Discovery within the Merck Research Labs, where she worked on the development of selective estrogen receptor modulators for hormone replacement therapy, the mechanism of action of ivermectin and the role of somatostatin receptors in diabetes and diabetic complications.
Within the Licensing and External Research department, Susan is currently assigned as the Licensing Scout for the Midwest US and Mid-Atlantic US covering all therapeutic areas of interest to Merck. In her previous role as Chairperson of the Neuroscience Review and Licensing Committee, she identified external licensing opportunities aligned with Merck’s priorities in Neuroscience; she coordinated due diligence team audits and reports for senior Merck management and provided scientific input to Merck’s Corporate Licensing commercial team charged with executing licensing agreements. She made significant contributions to the identification and execution of the following Major License Agreements:
- Neuromed NMED-160 patent license and research collaboration
- Harvard University visual cycle inhibitor patent license
- Gladstone Institute of Neurological Disease patent license and research collaboration covering ApoE mechanisms involved in neurodegenerative diseases
- Addex mGluR5 patent license covering mGluR5 PAMs for schizophrenia
- Addex mGluR4 patent license and research collaboration covering mGluR4 PAMs for Parkinson’s disease
- Lycera patent license and research collaboration covering RORgt inhibitors to treat autoimmune diseases
Susan was born and raised in Detroit, Michigan and obtained her degrees from the University of Michigan (BS) and the University of Notre Dame (PhD).